Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

Technology appraisal guidance
Reference number: TA269
Published: 12 December 2012
Last updated: 01 January 2015

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Appendix A - GE decision paper - January 2015

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Appendix A - GE decision paper - January 2015

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Appendix A - GE decision paper - January 2015
19 January 2015
(73.68 Kb 21 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 15 January 2015